Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.26355/eurrev_202007_22293 http://scihub22266oqcxt.onion/10.26355/eurrev_202007_22293 32744716!ä!32744716 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Eur+Rev+Med+Pharmacol+Sci 2020 ; 24 (14): 7880-7885 Nephropedia Template TP {{tp|p=32744716|t=2020. SARS-CoV-2 vs SARS-CoV-1 management: antibiotics and inflammasome modulators potential |pdf=|usr=}}{{32744716}} gab.com Text SARS-CoV-2 vs SARS-CoV-1 management: antibiotics and inflammasome modulators potential JO: Eur Rev Med Pharmacol Sci http://www.kidney.de/pget.php?&tw=1&pmid=32744716 #FOAvip The coronavirus SARS-CoV-2 at the origin of COVID-19 shares more than 70% genetic similarity with SARS-CoV-1 that was at the origin of 2003 SARS. Infection-associated symptoms are very similar between SARS and COVID-19 diseases and are the same as community-acquired pneumonia symptoms. Antibiotics were empirically given to SARS patients in the early stages of the pathology whereas a different strategy has been decided in the management of COVID-19 pandemic with a worldwide shutdown. The cytokine storm, both identified in SARS and COVID-19 severe cases, is generated through inflammasome activation, which opens therapeutic perspectives to counteract the pathogenic inflammation. As corticoids have numerous side effects that limit their use, focusing on anti-inflammasome agents could represent a safer alternative for patients with severe COVID-19. Twit Text FOAVip SARS-CoV-2 vs SARS-CoV-1 management: antibiotics and inflammasome modulators potential ????Eur Rev Med Pharmacol Sci http://www.kidney.de/pget.php?&tw=1&pmid=32744716 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32744716 #FOAvip English Wikipedia <ref>{{Cite pmid|32744716}}</ref> SARS-CoV-2 vs SARS-CoV-1 management: antibiotics and inflammasome modulators potential #MMPMID32744716 Rat P; Olivier E; Dutot M Eur Rev Med Pharmacol Sci 2020[Jul]; 24 (14): 7880-7885 PMID32744716show ga The coronavirus SARS-CoV-2 at the origin of COVID-19 shares more than 70% genetic similarity with SARS-CoV-1 that was at the origin of 2003 SARS. Infection-associated symptoms are very similar between SARS and COVID-19 diseases and are the same as community-acquired pneumonia symptoms. Antibiotics were empirically given to SARS patients in the early stages of the pathology whereas a different strategy has been decided in the management of COVID-19 pandemic with a worldwide shutdown. The cytokine storm, both identified in SARS and COVID-19 severe cases, is generated through inflammasome activation, which opens therapeutic perspectives to counteract the pathogenic inflammation. As corticoids have numerous side effects that limit their use, focusing on anti-inflammasome agents could represent a safer alternative for patients with severe COVID-19. |Adrenal Cortex Hormones/therapeutic use[MESH] |Anti-Bacterial Agents/*therapeutic use[MESH] |Betacoronavirus/isolation & purification[MESH] |COVID-19[MESH] |Coronavirus Infections/*drug therapy/epidemiology[MESH] |Humans[MESH] |Inflammasomes/chemistry/metabolism[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy/epidemiology[MESH] |Purinergic P2X Receptor Antagonists/therapeutic use[MESH] |Receptors, Purinergic P2X7/chemistry/metabolism[MESH] |SARS-CoV-2[MESH] |Severe Acute Respiratory Syndrome/*drug therapy/epidemiology/virology[MESH]SARS-CoV-2 vs SARS-CoV-1 management: antibiotics and inflammasome mod(epmc).pdf DeepDyve Pubget Overpricing